The etiology of dilated cardiomyopathy (DCM) can be grouped as either genetic or nongenetic. More than 50 pathogenic genes have been described, with sarcomeric and lamin A/C mutations being the most common. Mutation carriers for genetic DCM are often asymptomatic until cardiac disease manifests with heart failure, arrhythmias, or sudden cardiac death. Preventive strategies are promising but can only be applied and tested adequately if genetic DCM can be diagnosed at an early stage. Early diagnosis of mutation carriers that may develop overt DCM requires advanced imaging techniques that can detect subtle structural and functional abnormalities. Advanced echocardiographic techniques such as tissue Doppler imaging and speckle tracking strain analysis permit early detection of functional abnormalities, whereas cardiovascular magnetic resonance techniques provide information on tissue characterization and myocardial energetics that may be altered at an early stage. Furthermore, nuclear imaging techniques provide information on cellular function (metabolism, perfusion). Once the diagnosis of overt DCM has been established, various imaging parameters such as echocardiography-based myocardial mechanics and cardiovascular magnetic resonance-based tissue characterization have shown incremental benefit to left ventricular ejection fraction in risk stratification. Further research is required to understand how imaging techniques may help to choose management strategies that could delay progression when instituted early in the course of the disease. The present article reviews the role of imaging in the risk stratification of genetic DCM in general, with specific emphasis on DCM associated with neuromuscular disorders.
D
ilated cardiomyopathy (DCM) is defined as "left ventricular (LV) or biventricular systolic dysfunction and dilation that are not explained by abnormal loading conditions or coronary artery disease." 1 Ischemic heart disease is therefore excluded by definition, and etiologies of DCM are divided into 2 major groups: genetic versus nongenetic. 1 The distinction between genetic and nongenetic DCM is sometimes less clear because the likelihood of certain nongenetic etiologies (eg, chemotherapy) of causing DCM can be superimposed on the genetic susceptibility of an individual. 1 More than 50 pathogenic genes have been described, with sarcomeric and lamin A/C mutations being the most common, but defects of the desmosome, nucleus, mitochondrion, lysosome, and ion channels are also associated with the development of DCM. 2, 3 More than 1 pathogenic mutation may be present in a single individual, and this may be (at least in part) responsible for the large variation in penetrance of many of the genetic defects causing DCM. 4 The clinical manifestations of a genetic defect can vary from being preclinical (mutation carrier without clinical manifestations, LV dilation without hypokinesia or arrhythmias) to clinical (hypokinetic but nondilated cardiomyopathy or DCM). 1 The entity of hypokinetic but nondilated cardiomyopathy has recently been formally defined as "hypokinesia without significant LV dilation." 1 Early diagnosis of mutation carriers who may develop overt DCM require advanced imaging techniques that detect subtle structural and functional abnormalities. Advanced echocardiographic techniques such as tissue Doppler imaging and speckle tracking strain analysis permit early detection of functional abnormalities, whereas cardiovascular magnetic resonance (CMR) techniques provide information on tissue characterization and myocardial energetics that may be altered at an early stage. Furthermore, nuclear imaging techniques provide information on cellular function (metabolism, perfusion). The evidence supporting these imaging techniques in the diagnosis and risk stratification of patients with DCM is accumulating, specifically in DCM associated with neuromuscular disorders (genetics and extracardiac features) ( Table 1) . [5] [6] [7] The present article reviews the role of imaging in the early diagnosis and risk stratification in established disease of patients with DCM associated with neuromuscular disorders.
EARLY DIAGNOSIS OF VENTRICULAR DYSFUNCTION IN DCM ASSOCIATED WITH NEUROMUSCULAR DISORDERS
Early diagnosis is integral to the process of risk stratification in DCM because patients often remain asymptomatic until cardiac disease manifests with heart failure, life-threatening arrhythmias, or sudden cardiac death. 8 The onset or progression of ventricular systolic dysfunction and the development of myocardial fibrosis may be slowed by an early start of therapy resulting eventually in improved prognosis.
Examples include the early use of systemic steroids, angiotensin-converting enzyme (ACE) inhibitors or β-blockers in patients with Duchenne muscular dystrophy (DMD). [9] [10] [11] [12] [13] [14] [15] Barber et al 15 demonstrated in 462 patients with DMD that every year of steroid treatment decreased the probability of developing cardiomyopathy 10 In a similar fashion, either an ACE inhibitor or a β-blocker improved LV fractional shortening in patients with DMD and Becker muscular dystrophy and cardiac involvement (P<0.05).
14 Experimental therapies hold promise of influencing disease processes when initiated early (eg, the membrane sealant polaxamer, which repairs damaged biological membranes, growth hormone treatment, or gene therapy in DMD). [16] [17] [18] Approaches to early diagnosis have focused on advanced imaging techniques to demonstrate abnormalities of cardiac structure, as well as mechanical and cellular function.
Cardiac Structure
Increased extracellular matrix and fibrosis of the myocardium are the hallmarks of changes in the cardiac structure in DCM. Myocardial late gadolinium enhancement (LGE) allows the noninvasive detection of replacement myocardial fibrosis with CMR. 19 Segmental LGE has been demonstrated in individuals with DMD and Becker muscular dystrophy before the onset of LV or right ventricular systolic dysfunction and may therefore indicate early disease (Figure 1) . [19] [20] [21] [22] [23] Similarly, segmental LGE has been visualized in carriers of lamin A/C mutations and in patients with myotonic dystrophy and preserved LVEF. [24] [25] [26] [27] Segmental LGE has also been detected in mitochondrial diseases with cardiac involvement (chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome) but normal LV systolic function. 28 However, in the early phases of DCM, reactive fibrosis (an increase of interstitial space by deposition of collagen) rather than replacement fibrosis is present. This reactive fibrosis is detected with T1 mapping CMR imaging techniques. For example, longitudinal relaxation is described by a T1 recovery curve, and the time constant (when 63% of recovery has occurred) of such a curve can be represented by a pixelwise, color-coded map (a T1 map). 29 Increased reactive fibrosis will result in long T1 times in native T1 maps (acquired without the use of a gadolinium-based contrast agent). In contrast, when T1 maps are registered after gadoliniumbased contrast media administration, the T1 times are shorter in segments with increased fibrosis as compared with normal myocardium. 30 Different CMR sequences are used in T1 mapping (eg, modified Look-Locker Inversion recovery and shortened modified Look-Locker Inversion). 29 The extracellular volume fraction (ECV) of the myocardium, which is a measure of the size of the extracellular space, can be calculated from the native myocardial and precontrast blood T1 values, the postcontrast myocardial and blood T1 values, as well as the hematocrit. 31 Interstitial, reactive myocardial fibrosis, representing an early form of myocardial damage, can be both diagnosed and quantified by T1 mapping and ECV calculation. 32 An elevated ECV was found in lamin A/C mutation carriers with normal LV systolic function and even in some individuals without LGE. Therefore, ECV may be an even more sensitive marker of early disease than LGE. 33 An elevated ECV and native T1 values have also been documented in patients with DMD and normal LV systolic function (including some without LGE) (Figure 2) . [34] [35] [36] T1 mapping may be particularly suited to the investigation of cardiac involvement in myotonic dystrophy because fibrosis is most frequently diffuse, rather than localized, in this condition. 37 Postcontrast T1 values were significantly lower in a group of individuals diagnosed with type 1 and type 2 myotonic dystrophy and normal LV systolic function compared with controls. 37 Segmentally increased ECV and focal lipid deposits have been described in patients affected with type 2 myotonic dystrophy and preserved LV systolic function, including regions without LGE, supporting the concept that reactive, diffuse fibrosis is a sensitive marker of cardiac involvement. Myocardial tissue characterization can also be performed with echocardiography by analysis of the reflected ultrasound signal, which is known as integrated backscatter (IBS). Two parameters are generally measured in the anteroseptal and posterior walls of the left ventricle, which include the magnitude of cyclic variation and the IBS intensity (both expressed in dB). 38, 39 A decrease in the magnitude of cyclic variation denotes an increase in myocardial collagen content, although it can be influenced by myocardial water content, myofibril architecture, and contractility, whereas the degree of IBS intensity shows a correlation with myocardial fibrosis. 38, 39 In a study of 25 patients with DMD, the IBS intensity was higher and the magnitude of cyclic variation lower in the outer half of the LV myocardium compared with controls, suggesting epicardial fibrosis. 38 Similarly, a lower magnitude of cyclic variation and a higher IBS intensity were noted in 20 children with DMD compared with age-matched controls ( Figure 3 ).
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Mechanical Function
Although LVEF is the measure of choice to characterize LV systolic function, subtle changes in myocardial function can be detected with more sensitive measures based on deformation and tissue velocity imaging. Myocardial deformation can be quantified by strain, which reflects a unitless measure of change in dimension. 41 Echocardiographic strain imaging is most commonly performed with speckle tracking echocardiography. Myocardial speckles, which arise from the interaction of ultrasound and myocardium, are identified by imaging software, and their displacement is followed from frame to frame. 41 Strain is most commonly reported in the longitudinal, radial, or circumferential directions of LV deformation and can be reported at segmental (pertaining only to one segment of the ventricle) or global (reflecting all segments of the ventricle) levels. 42 Global LV longitudinal strain is the deformation parameter that has been most extensively studied, and it demonstrates the best reproducibility. Myocardial strain imaging has demonstrated value in both the early diagnosis and risk stratification of various cardiac diseases, including genetic and nongenetic cardiomyopathies. 42 Different CMR techniques can also be used to measure strain (eg, myocardial tagging and feature tracking). 43, 44 Impaired LV longitudinal, circumferential, and radial strain, as well as reduced longitudinal and radial strain rates (using speckle tracking echocardiography), have been reported in individuals with DMD and normal LVEF on echocardiography or CMR. [45] [46] [47] [48] [49] [50] Impaired segmental LV systolic and diastolic radial strain rates were noted in patients with Becker muscular dystrophy and a normal LVEF. 51 Reduced LV segmental, circumferential strain (despite normal LVEF) was observed in patients with Emery-Dreifuss muscular dystrophy because of lamin A/C mutations. 52 An abnormal transmural LV strain pattern (comparing endo-, mid-, and epicardial strain values) was identified in patients with DMD and preserved LVEF. 53 The myocardial tissue velocity can be determined by tissue Doppler echocardiography during both systole and diastole. 54, 55 Systolic myocardial tissue velocity is a reflection of longitudinal LV function, which is caused by endocardial fiber shortening, whereas diastolic myocardial tissue velocity is a surrogate of early diastolic LV relaxation. 56 Impaired LV systolic and diastolic myocardial tissue velocities are markers of early cardiac disease and have been associated with outcome in various cardiac disorders. [56] [57] [58] [59] Systolic and diastolic LV tissue velocities are reduced in patients with DMD and Friedreich ataxia who display a normal LVEF. 46, 47, [60] [61] [62] Similarly, systolic and diastolic LV tissue velocities are impaired in patients with myotonic dystrophy with a normal LVEF. 63, 64 In a normal heart, LV endocardial velocity (measured with tissue Doppler imaging) is greater than epicardial velocity, which reflects the rate of increase in wall thickening with contraction. The myocardial velocity gradient is the difference in myocardial velocity between the endo-and epicardium, divided by the myocardial wall thickening, and is an index of regional myocardial function. 65 Abnormal myocardial velocity gradients were identified in the interventricular septum, as well as the posterior wall of the left ventricle, in patients with Friedreich ataxia, DMD, and Emery-Dreifuss muscular dystrophy (in the presence of a lamin A/C mutation) and preserved LV systolic function.
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Cellular Function
Phosporus-31 magnetic resonance spectroscopy ( 31 P-MRS) allows noninvasive examination of cardiac energetics by quantification of high-energy phosphate metabolites. 68 Altered cardiac energetics are early markers of cardiomyopathy, often preceding morphological and overt functional abnormalities. Evaluation of LV myocardial metabolism can be obtained on a cellular level with 31 P-MRS. 69 Current 1.5T and 3T scanners do not allow voxel sizes with a spatial resolution, which is high enough to produce spectra of individual myocardial segments (according to the American Heart Association 17-segment model); subsequently, a volume of interest is placed in either the anterior LV wall or the interventricular septum. 70, 71 Peaks in the 31 P-MRS reflect the concentrations of the 3 phosphorous atoms of ATP (ie, γ-ATP, α-ATP, and β-ATP), as well as phosphocreatine (PCr) (Figure 4) . 68 From the ATP and PCr concentrations, the PCr:ATP ratio can be calculated, which is influenced by abnormal cardiac metabolism in disease states. The reaction equilibrium of the creatine kinase reaction favors the synthesis of ATP rather than PCr, leading to a reduction in PCr when ATP demand is in excess of ATP supply, the consequence of which is a decrease in the PCr:ATP ratio. 68 Some carriers of Xp21 mutations (the gene encoding dystrophin, causing DMD and Becker muscular dystrophy) with normal LV wall thickness and systolic and diastolic function nevertheless manifest a reduced PCr:ATP ratio. 72 Therefore, abnormal cardiac energetics, diagnosed with 31 P-MRS, may also be a signal of early cardiac involvement in such patients. Similarly, a reduced myocardial PCr:ATP ratio has been detected in patients with myotonic dystrophy, Friedreich ataxia, and P-MRS can be used to interrogate skeletal muscle energetics, thereby allowing a comprehensive assessment of cardioneuromuscular disorders. 69 Nuclear imaging can also evaluate cellular integrity and function. Global and regional myocardial perfusion can be visualized with gated imaging with singlephoton emission computed tomography (SPECT). 74 Dystrophin-deficient myocardium is more vulnerable to pressure overload than normal myocardium, particularly in the LV inferior wall, which is exposed to greater wall stress than other segments of the LV. 75 Patients with DMD and Becker muscular dystrophy may show myocardial perfusion defects in the LV inferior wall on 99m technetium SPECT imaging. 75 In addition, the myocardial cells of the LV apical segments are rich in dystrophin protein and may also show myocardial perfusion defects ( Figure 5 ). This technique has shown potential for the early identification of cardiac involvement, as well as for monitoring treatment response to systemic steroid therapy in DMD. 75 After a follow-up period of 2 years in patients with DMD who received systemic steroids, a significant improvement in myocardial perfusion was detected, whereas no change was evident in LV dimensions or LVEF. 75 Positron emission tomography (PET) imaging using 13 N-ammonia as a tracer can image myocardial perfusion, as well as 99m technetium SPECT; the advantage of PET over SPECT is that the former permits absolute quantification of processes, whereas the latter provides semiquantitative measurements. 74 In addition, myocardial metabolism can be investigated with 18 F-fluorodeoxyglucose PET. 74 Patients with DMD and normal LVEF have shown reduced myocardial perfusion in the LV posterobasal and posterolateral segments on 13 N-ammonia PET, whereas the uptake of 18 F-fluorodeoxyglucose was increased, suggesting the presence of regional metabolic alteration in uptake and trapping, a reduction in regional blood flow or both.
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RISK STRATIFICATION IN ESTABLISHED DISEASE
Once a diagnosis of genetic DCM has been established, risk stratification is of paramount importance. Risk may entail ventricular arrhythmias, incident heart failure, or sudden cardiac death. Various imaging parameters of myocardial structure and function have been identified that may be useful in risk stratification.
Cardiac Structure
LGE of the interventricular septum (denoting myocardial fibrosis) was associated with ventricular arrhythmias in a cohort of lamin A/C mutation carriers with a normal LVEF (LGE was only present in patients experiencing ventricular arrhythmias; P=0.007), and may therefore help to risk stratify these individuals, who are at high risk of ventricular arrhythmias and sudden cardiac death. 26 Patients with Friedreich ataxia and cardiac involvement experienced more frequent cardiac symptoms in the presence of LGE: After 12 months of follow-up, 3 of 14 (20%) patients with LGE experienced cardiac events, whereas no events were recorded in LGE-negative patients (P=0.1). 77 The presence as well as the extent of LGE may be important in the quantification of risk: Transmural LGE in patients with DMD or Becker muscular dystrophy was an independent predictor of ventricular tachycardia and hospitalization for heart failure (hazard ratio, 2.89; 95% confidence interval, 1.09-7.68; P=0.033) regardless of preserved or reduced LVEF. 78 The presence of LGE in patients with DMD has been associated with the development of heart failure symptoms and impaired LVEF (64±6% in LGE-negative patients versus 57±7% in LGE-positive patients; P=0.014), whereas the extent of LGE has been correlated with the degree of decline in LVEF over time (2.2±0.31% decline per year in LGE-positive patients versus 0.21±0.22% decline per year in LGE-negative patients; P=0.34). 79, 80 LGE is therefore a potential marker of the presence and progression of heart failure. 79, 80 An increased ECV has been associated with arrhythmias (odds ratio, 1.97; 95% confidence interval, 1.21-32.22; P=0.032) in patients with Becker muscular dystrophy, whereas the presence of LGE per se (considered in a binary fashion) was not. 81 Although the presence of LGE is useful in the diagnosis of cardiac involvement in Becker muscular dystrophy, the quantification of ECV may have more utility in risk stratification. 81 
Mechanical Function
In 88 patients with DMD or Becker muscular dystrophy and cardiac involvement, LVEF independently predicted ventricular tachycardia and hospitalization for heart failure (hazard ratio, 0.94; 95% confidence interval, 0.89-0.97; P=0.001). 78 Similarly, an LVEF <45% was associated with appropriate implantable cardioverterdefibrillator therapy and sudden cardiac death (hazard ratio, 4.4; 95% confidence interval, 1.7-11.0; P=0.021) in lamin A/C mutation carriers. 82 However, in patients with preserved LVEF, strain imaging may refine the risk stratification of these patients. Longitudinal, septal (averaged from 4 septal segments) strain, measured with speckle tracking echocardiography, was reduced when compared with longitudinal strain in nonseptal segments of the LV in 41 lamin A/C mutation carriers ( Figure 6) . 26 In the same study, reduced septal strain correlated with the PR interval on electrocardiography (R=0.41, P=0.03), whereas a prolonged PR interval was associated with ventricular arrhythmias (P<0.001). 26 In addition, LV mechanical dispersion measures the standard deviation of the time to peak systolic deformation of 16 to 17 segments of the left ventricle and is an application of strain imaging performed with speckle tracking echocardiography. 83, 84 LV mechanical dispersion is an indicator of the degree of mechanical heterogeneity and has been associated with ventricular arrhythmias in a number of different cardiac pathologies. 83, 85, 86 Increased mechanical dispersion has been reported in lamin A/C mutation carriers with ventricular arrhythmias as compared with mutation carriers without ventricular arrhythmias (49±14 ms versus 38±10 ms; P=0.02), whereas LVEF alone could not distinguish between individuals with and without ventricular arrhythmias (Figure 7) . 
CLINICAL INTEGRATION OF CARDIAC IMAGING IN RISK STRATIFICATION OF GENETIC DCM ASSOCIATED WITH NEUROMUSCULAR DISORDERS
Position statements on the diagnosis, risk stratification, and treatment of DCM (including the role of genetic testing) have been published by the American Heart Association and the European Society of Cardiology. 1, 8, 88 Based on the previously mentioned position statements, an algorithm can be proposed that integrates cardiac imaging modalities into the risk stratification of genetic DCM (Figure 8 ). Although there are no specific position statements for genetic DCM associated with neuromuscular disorders, the principles are similar, and therefore it can be applied to these genetic conditions. This algorithm includes both early diagnosis and risk stratification of established disease. In general, it is not recommended to screen children <10 to 12 years of age. 88 Two approaches exist toward screening family members of an index patient (the proband) with genetic DCM: genetic and clinical cascade screening. Genetic cascade screening involves testing family members for the specific mutation present in the proband. If the result is negative, then no risk exists for development of the specific genetic DCM, and further screening is not required. 88 If genetic screening is not available, the mutation is present, or no diseasecausing mutation can be found in the proband, then clinical cascade screening is indicated. This involves history taking, physical examination, a 12-lead ECG, and transthoracic echocardiography.
If the LVEF is reduced (≤50%) or the LV end-diastolic diameter or volume is increased, then the presence of disease is established.
1 Genetic testing to risk stratify patients with established disease is of limited utility, except in lamin A/C mutations, which portend a high risk. 88 Advanced cardiac imaging can be used to further risk stratify these individuals by means of early diagnosis: LV longitudinal strain and mechanical dispersion can be derived from routinely acquired, 2-dimensional echocardiographic data without additional cost. When echocardiography does not provide a definitive answer regarding the presence/absence of disease, or when the echocardiographic window is suboptimal, cardiovascular magnetic resonance can be considered.
If the LVEF is preserved (>50%) or the left ventricle is not dilated, clinical cascade screening has to be re- peated at 1 to 2 yearly intervals until 20 years of age and every 2 to 5 years until 50 to 60 years of age. 88 Transthoracic echocardiography is included in each screening event. For the risk stratification of established disease, assessment of IBS, strain, and myocardial velocities on clinically acquired echocardiographic data could help identify patients with increased risk of progression of the disease or ventricular arrhythmias. However, the impact of these measures on the clinical management of the patients is still being evaluated. Similar to risk stratification for established disease, CMR can be performed when uncertainty remains. If contrast is administered for LGE, postcontrast T1 maps and ECV calculation can be performed. Strain imaging and 31 P-MRS are promising but still considered investigational techniques. Nuclear imaging techniques can be considered if requested for additional indications (eg, exclusion of coronary artery disease as a potential cause of cardiomyopathy).
The clinical applicability of various imaging techniques is summarized in Table 2 . In general, the reproducibility of imaging parameters is good in genetic DCM (Table I in the online-only Data Supplement). In the absence of studies comparing different imaging modalities and parameters for risk stratification of genetic DCM, a specific order of testing cannot be recommended at this moment, and the sequence of imaging modalities will depend more on the availability, cost, and concomitant indications, as discussed earlier.
CURRENT STATE OF KNOWLEDGE AND FUTURE PERSPECTIVES
Although the diagnostic role of cardiac imaging is well defined for genetic DCM, there are 2 evident research opportunities where imaging will play a pivotal role: the prediction of outcome with imaging parameters and the benefit of early therapy in the prevention (or inhibition of progression) of genetic DCM. Lack of data regarding early therapy may be partly ascribed to the absence of effective, directed therapies. Prospective trials will be required to obtain evidence that any directed therapy or standard heart failure therapy (eg, ACE inhibitors) improves patient outcomes when started early in the course of the disease. Treatment effects have generally been evaluated with only conventional functional imaging parameters (eg, LV fractional shortening or LVEF), although LV global longitudinal strain has been used to measure the effect of enalapril and carvedilol in patients with DMD and Becker muscular dystrophy. 14 Despite various imaging parameters providing data on risk stratification in established disease, prospective studies are also necessary to determine whether these data will translate into improved outcomes (eg, when used for guidance of primary prevention implantable cardioverter defibrillator placement).
Few studies have systematically studied multimodality imaging in a single mutation or disease entity to compare their relative usefulness in early diagnosis or risk stratification or to compare a single technique between different etiologies of genetic DCM. In summary, the following steps are required before cardiac imaging parameters can guide therapy for genetic DCM. Both conventional (LVEF) and novel (LV strain) parameters have to be evaluated for their ability to predict long-term outcome (development of symptoms, decrease in LV systolic function, ventricular arrhythmias, and mortality), especially in asymptomatic mutation carriers. In addition, a variety of therapies (ACE inhibitors and implantable cardioverter defibrillators) have to be evaluated for their abilities to influence the course of disease, either when instituted early in asymptomatic mutation carriers or in established disease that has been risk stratified with imaging techniques. Moreover, the impact of such therapies can be measured by imaging (eg, change in ECV) or mortality end points, and finally multicenter studies will be required.
Using imaging markers as therapeutic targets may prove especially useful because obtaining long-term follow-up of uncommon cardiomyopathies in multicenter studies will be challenging. Two lines of evidence suggest that imaging parameters could be useful as therapeutic targets. First, pharmacotherapy (β-blockers and systemic steroids) has been shown to reverse LV remodeling in genetic DCM (DMD and Becker muscular dystrophy). 12, 13 This likely reflects an inhibitory effect on myocardial fibrosis, and T1 mapping cardiac magnetic resonance techniques (including calculating ECV of the myocardium) have the potential to reflect a treatment effect. In addition, early therapy has been proven to delay the onset or slow the progression of systolic dysfunction in some types of genetic DCM (eg, systemic steroids and ACE inhibitors in patients with DMD).
9,10 Therefore, parameters from imaging techniques could be used to guide therapy.
CONCLUSIONS
Genetic DCM represents a substantial proportion of DCM. Affected individuals are at high risk for complications, and strategies to identify disease early and effectively risk stratify these patients are needed. A variety of cardiac imaging modalities have proven their ability to identify disease early, and they have shown promise in risk stratification. Further research is required to apply imaging techniques to the evaluation of management strategies that could delay progression when instituted early in the course of disease.
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